Vedolizumab for induction and maintenance of remission in Crohn’s disease
- 13 May 2020
- journal article
- research article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2020 (5)
- https://doi.org/10.1002/14651858.cd013611
Abstract
Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: The primary objective of this systematic review of the literature is to assess the efficacy and safety of vedolizumab in the induction and maintenance of remission in Crohn's disease.Keywords
This publication has 10 references indexed in Scilit:
- Interventions for maintenance of surgically induced remission in Crohn’s disease: a network meta-analysisCochrane Database of Systematic Reviews, 2019
- Pathogenesis of Crohn's diseaseF1000Prime Reports, 2015
- PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel DiseasesMedicine, 2014
- Vedolizumab for induction and maintenance of remission in ulcerative colitisCochrane Database of Systematic Reviews, 2014
- Risk of Natalizumab-Associated Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 2012
- Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic ReviewGastroenterology, 2012
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trialThe Lancet, 2008
- α4Integrins as Therapeutic Targets in Autoimmune DiseaseNew England Journal of Medicine, 2003
- Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7Gastroenterology, 1996
- Lymphocyte Homing and HomeostasisScience, 1996